Vanda Pharmaceuticals Inc
$ 5.20
-1.33%
04 Dec - close price
- Market Cap 307,302,000 USD
- Current Price $ 5.20
- High / Low $ 5.33 / 5.18
- Stock P/E N/A
- Book Value 7.89
- EPS -1.44
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.17 %
- 52 Week High 5.70
- 52 Week Low 3.81
About
Vanda Pharmaceuticals Inc. is a biopharmaceutical company based in Washington, D.C., focused on developing and commercializing innovative therapies for significant unmet medical needs, particularly in central nervous system and sleep disorders. The company boasts a robust pipeline of products and a commitment to advancing patient care through scientific expertise and strategic focus on niche markets. Vanda's dedication to enhancing patient outcomes positions it as a key player in the biopharmaceutical industry, with potential for sustainable growth and impactful contributions to healthcare.
Analyst Target Price
$11.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-07-31 | 2025-05-07 | 2025-02-13 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-07 | 2023-11-08 | 2023-07-27 | 2023-05-03 | 2023-02-08 |
| Reported EPS | -0.38 | -0.46 | -0.5 | -0.08 | -0.09 | -0.08 | -0.0718 | -0.04 | 0.0024 | 0.03 | 0.06 | 0.12 |
| Estimated EPS | -0.45 | -0.36 | -0.6 | -0.11 | -0.16 | -0.21 | 0.05 | -0.09 | -0.04 | -0.13 | 0.06 | 0.08 |
| Surprise | 0.07 | -0.1 | 0.1 | 0.03 | 0.07 | 0.13 | -0.1218 | 0.05 | 0.0424 | 0.16 | 0 | 0.04 |
| Surprise Percentage | 15.5556% | -27.7778% | 16.6667% | 27.2727% | 43.75% | 61.9048% | -243.6% | 55.5556% | 106% | 123.0769% | 0% | 50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VNDA
2024-06-27 18:57:00
Future Pak has withdrawn its offer to acquire Vanda Pharmaceuticals, citing a lack of engagement from the U.S. drugmaker. Vanda had previously rejected Future Pak's revised bid and adopted a shareholder rights plan to prevent a hostile takeover. Future Pak had increased the cash portion of its buyout offer and given Vanda a deadline to engage constructively.
2024-06-06 09:24:00
Vanda Pharmaceuticals Inc. confirmed receiving an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash. Vanda's Board of Directors will review this offer in consultation with financial and legal advisors to determine the best course of action for the company and its shareholders. Shareholders are advised that no action is required at this time.
2024-05-30 16:48:00
Vanda Pharmaceuticals announced the completion of the transfer of FDA marketing authorization for PONVORY® from a Johnson & Johnson Company. This allows Vanda to fully commercialize PONVORY® in the U.S. and begin clinical development programs for the treatment of various inflammatory disorders. Vanda plans to initiate commercial activities, including a specialty sales force and marketing program, in anticipation of a third-quarter 2024 launch for PONVORY® in relapsing forms of multiple sclerosis.
2024-05-28 00:00:00
Vanda Pharmaceuticals has once again rejected an updated acquisition offer from Future Pak, stating the proposal is "not in the best interests" of the business or its shareholders. This marks another refusal by the D.C.-based biotech firm regarding acquisition bids.
2024-04-22 15:46:00
The U.S. Supreme Court has declined to hear Vanda Pharmaceuticals' bid to revive patents for its sleep-disorder drug Hetlioz, which were previously invalidated in a dispute with generic drugmakers Teva and Apotex. The decision upholds a ruling by the U.S. Court of Appeals for the Federal Circuit and prevents the Supreme Court from reviewing the standard for patent "obviousness." Vanda expressed disappointment, emphasizing the importance of patent incentives for developing treatments, especially for rare diseases, while Teva welcomed the decision.
2024-01-31 00:00:00
Vanda Pharmaceuticals Inc. has petitioned the Supreme Court to clarify the standard for obviousness in patent law, specifically whether it requires "predictable" results or merely a "reasonable expectation of success." This petition stems from a Federal Circuit decision invalidating Vanda's patents for tasimelteon based on obviousness, citing clinical trials as prior art. The case highlights a potential conflict between current obviousness standards and the requirements for patentability under Section 112, particularly in the pharmaceutical industry where drug development is costly and unpredictable.
